Subsequently, in order to determine whether ATRX loss has prognostic value in CM we evaluated ATRX status in CM cases with recurrent disease versus CM cases without recurrent disease as well as CM cases with metastatic disease versus CM cases without the development of metastatic disease. This evidence concerns the gene ATRX and metastatic neoplasm.